LifeSci Capital Downgrades Ventyx Biosciences to Market Perform, Announces $14 Price Target

Benzinga · 5d ago
LifeSci Capital analyst Sam Slutsky downgrades Ventyx Biosciences (NASDAQ:VTYX) from Outperform to Market Perform and announces $14 price target.